Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) ...
Product Name : Cotempla
Product Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2023
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Sleep
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Prodrug of d-methylphenidate, is sole API in KP1077, a potential first-ever therapeutic treatment for Idiopathic Hypersomnia, a neurological disorder marked by significant, detrimental effects on nighttim...
Product Name : KP1077
Product Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Lead Product(s) : Methylphenidate
Therapeutic Area : Sleep
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Aytu BioScience
Deal Size : $44.9 million
Deal Type : Merger
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement
Details : Aytu adds Neos' established, multi-brand ADHD portfolio which includes Adzenys XR-ODT and Cotempla XR-ODT, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care se...
Product Name : Cotempla XR-ODT
Product Type : Small molecule
Upfront Cash : Undisclosed
December 10, 2020
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Aytu BioScience
Deal Size : $44.9 million
Deal Type : Merger
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Agreement
Details : The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.
Product Name : Concerta
Product Type : Small molecule
Upfront Cash : Undisclosed
September 29, 2020
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?